Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02685969 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Active, Not Recruiting to Recruitingv10 Show 4 more changesShow less
    • Enrollment target: 363 to 570
    • Primary completion date: Dec 20, 2019 to Dec 31, 2026
    • Study completion date: Dec 31, 2024 to Dec 31, 2027
    • Site details revised
  2. Study completion date: Dec 31, 2023 to Dec 31, 2024v9
  3. Study completion date: Dec 31, 2022 to Dec 31, 2023v8
  4. Re-verified, no change to tracked fieldsv7
  5. Study completion date: Dec 31, 2020 to Dec 31, 2022v6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date changed from estimate of Mar 1, 2019 to Dec 20, 2019v5 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 440 to confirmed 363
    • Study completion date: Mar 1, 2020 to Dec 31, 2020
    • Site details revised
  2. Primary completion date: Mar 2019 to Mar 1, 2019
    • Study completion date: Mar 2020 to Mar 1, 2020
    v4
  3. Trial status: Not Yet Recruiting to Recruitingv3 Show 5 more changesShow less
    • Start date: Nov 2016 to Mar 1, 2017
    • Primary completion date: Nov 2018 to Mar 2019
    • Study completion date: Jun 2019 to Mar 2020
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
  4. Primary completion date: Apr 2016 to Nov 2018
    • Start date: Apr 2016 to Nov 2016
    • Study completion date: Apr 2016 to Jun 2019
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression. Cross-sectional and single arm study performed on a subgroup of individuals recruited in the ALFA project. Study without therapeutic interest for the research participants (440 participants of the ALFA project who have been selected for being cognitively healthy and in their vast majority are direct descendants of patients diagnosed with Alzheimer's Disease). Each study candidate will be selected from the ALFA project (STUDY 45-65 FPM/2012) according to their clinical characteristics, their compliance to selection criteria and their desire to participate in this study. After signing this study's specific informed consent form, the neuropsychological screening and the brain MRI acquisition will be performed. Once all inclusion criteria are checked, the PET scans with 18F-Flutemetamol and 18F-FDG will be performed
Trial Details
NCT Number NCT02685969
Lead Sponsor Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Collaborators: Hospital Clinic of Barcelona, General Electric
Conditions
(from sponsor)		 Alzheimer's Disease
Related terms Alzheimer Disease
Enrollment 570 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov